Literature DB >> 25336164

Complementary use of MALDI-TOF MS and real-time PCR-melt curve analysis for rapid identification of methicillin-resistant staphylococci and VRE.

Wai-Sing Chan1, Tsz-Ming Chan1, Tsz-Wan Lai1, Jasper Fuk-Woo Chan2, Raymond Wai-Man Lai3, Christopher Koon-Chi Lai4, Bone Siu-Fai Tang5.   

Abstract

OBJECTIVES: To develop a rapid method for routine screening of methicillin-resistant staphylococci and VRE for clinical isolates and positive blood cultures.
METHODS: Our method consisted of two parts: MALDI-TOF MS was used for identification of staphylococci and enterococci, followed by antibiotic resistance detection by real-time PCR-melt curve analysis without DNA extraction. The latter part included a triplex reaction for staphylococcal culture isolates (mecA, mecALGA251 and Panton-Valentine leucocidin genes), dual PCR of mecA/mecALGA251 and nuc genes for staphylococcal blood cultures, and a duplex reaction for enterococci (vanA and vanB genes). A total of 124 clinical isolates and 56 positive blood cultures were tested. MALDI-TOF MS was performed using Microflex LT (Bruker Daltonik, Bremen, Germany) and Rotor-Gene Q (Qiagen, Hilden, Germany) was used for real-time PCR-melt curve analysis. The total assay time was <2.5 h.
RESULTS: The results revealed 100% concordance with antibiotic susceptibility testing or other reference methods for all culture isolates and enterococcal blood cultures. The percentage of concordance for staphylococcal blood cultures was 97.5%.
CONCLUSIONS: The method described herein was fast, economical, reliable and capable of detecting mecALGA251, vanB1 and vanB2 genotypes, which are not included in most commercial assays. Large-scale screening is required to further test the performance of this protocol, especially for genotypes that are infrequently encountered.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Keywords:  MRSA; VRE; antibiotic resistance; mixed blood cultures; multiplex

Mesh:

Substances:

Year:  2014        PMID: 25336164     DOI: 10.1093/jac/dku411

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Development of a Real-Time PCR Protocol Requiring Minimal Handling for Detection of Vancomycin-Resistant Enterococci with the Fully Automated BD Max System.

Authors:  Alexander H Dalpke; Marjeta Hofko; Stefan Zimmermann
Journal:  J Clin Microbiol       Date:  2016-06-29       Impact factor: 5.948

2.  ATR-FTIR Spectroscopy Highlights the Problem of Distinguishing Between Exophiala dermatitidis and E. phaeomuriformis Using MALDI-TOF MS.

Authors:  Çağrı Ergin; Yaşar Gök; Yasemin Bayğu; Ramazan Gümral; Betil Özhak-Baysan; Aylin Döğen; Dilara Öğünç; Macit Ilkit; Seyedmojtaba Seyedmousavi
Journal:  Microb Ecol       Date:  2015-09-15       Impact factor: 4.552

3.  Evaluation of a matrix-assisted laser desorption ionization-time of flight mass spectrometry assisted, selective broth method to screen for vancomycin-resistant enterococci in patients at high risk.

Authors:  Tsi-Shu Huang; Susan Shin-Jung Lee; Chia-Chien Lee; Chiu-Yen Chen; Fang-Chen Chen; Bao-Chen Chen; Cheng Len Sy; Kuan-Sheng Wu
Journal:  PLoS One       Date:  2017-06-13       Impact factor: 3.240

4.  Antibiotic Stewardship Related to Delayed Diagnosis and Poor Prognosis of Critically Ill Patients with Vancomycin-Resistant Enterococcal Bacteremia: A Retrospective Cohort Study.

Authors:  Mu-Chun Yang; Yao-Kuang Wu; Chou-Chin Lan; Mei-Chen Yang; Sheg-Kang Chiu; Ming-Yieh Peng; Wen-Lin Su
Journal:  Infect Drug Resist       Date:  2022-03-01       Impact factor: 4.003

5.  Rapid Identification and Multiple Susceptibility Testing of Pathogens from Positive-Culture Sterile Body Fluids by a Combined MALDI-TOF Mass Spectrometry and Vitek Susceptibility System.

Authors:  Yueru Tian; Bing Zheng; Bei Wang; Yong Lin; Min Li
Journal:  Front Microbiol       Date:  2016-04-20       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.